上皮成長因子EGFが癌細胞の浸潤,転移能に及ぼす影響 第2報 EGF長期間処理による悪性形質獲得機序の検討

  • 永易 裕樹
    北海道医療大学歯学部口腔外科学第二講座
  • 柴田 敏之
    北海道医療大学歯学部口腔外科学第二講座
  • 有末 眞
    北海道医療大学歯学部口腔外科学第二講座
  • 河野 峰
    北海道医療大学歯学部口腔外科学第二講座
  • 加藤 元康
    北海道医療大学歯学部口腔外科学第二講座
  • 中井 一元
    北海道医療大学歯学部口腔外科学第二講座
  • 中田 大地
    北海道医療大学歯学部口腔外科学第二講座
  • 小西 亮
    北海道医療大学歯学部口腔外科学第一講座
  • 奥村 一彦
    北海道医療大学歯学部口腔外科学第一講座

書誌事項

タイトル別名
  • Effects of epidermal growth factor(EGF) on invasive and metastatic ability of tumor cells. Part 2: Mechanisms of malignant phenotype acquisition by long-term EGF treatment.
  • Part 2: Mechanisms of malignant phenotype acquisition by long-term EGF treatment
  • 第2報, EGF長期間処理による悪性形質獲得機序の検討

この論文をさがす

抄録

We have previously reported that epidermal growth factor (EGF) enhanced the invasive and metastatic abilities of regressor ER-1 cells and that ER-1 cells might acquire stable malignant phenotypes after long-term EGF treatment. In this study, we studied the mechanisms of the malignant phenotype acquisition by long-term EGF treatment.<BR>EGF enhanced the chemotactic response of ER-1 cells toward culture supernatant conditioned with rat lung endothelial cells in a dose-dependent fashion and also enhanced invasiveness into the reconstituted basement membrane (MatrigelTM) in a similar manner. Furthermore, when ER-1 cells were cultured in the presence of EGF for a month (1M EGF ER-1), they acquired stable invasiveness. In EGF binding assay using 125I-EGF, the numbers of EGF receptors were similar for ER-1 cells and 1 M EGF ER-1 cells, which expressed both highand low-affinity receptors. RT-PCR analysis demonstrated that mRNA expression of EGF receptors was similar for both ER-1 cells and 1M EGF ER-1 cells. Drug-resistance tests using c-SST-2 cells (parent cells of ER-1) revealed that colonies resistant to 6-thioguanine and ouabain appeared after long-term EGF treatment (one month).<BR>These results suggest that long-term EGF treatment may affect the genomic alteration of ER-1 cells and that these may acquire stable malignant phenotypes

収録刊行物

参考文献 (22)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ